Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research.

Natalia Kunst Natasha K StoutGrace O'BrienKurt D Christensen Pamela M McMahon Ann Chen WuLisa R DillerJennifer M Yeh

Published in: Journal of the National Cancer Institute (2022)

We found that TP53-NBS could be cost-effective; however, our findings suggest that further research is needed to reduce the uncertainty in the potential health outcomes and costs associated with TP53-NBS.

Keyphrases

copy number
gene expression
dna damage
climate change
dna methylation